PepGen Inc. (PEPG) AI Stock Analysis

• Market Cap: $425.75M
• Dividend Yield: N/A
• Average Volume (3M): 6.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 4.71%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 69,115,295
• 10 Day Avg. Volume: 930,736
• 30 Day Avg. Volume: 6,679,177
• PEG Ratio: 0.12
• Price to Book (P/B): 1.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.36
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -562.93
• Enterprise Value/Ebitda: -4.24
• 1Y Price Target: $11.00
• Price Target Upside: 97.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.33
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.50 ▼(-1.26% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is primarily held down by weak financial performance (no revenue, large ongoing losses and heavy cash burn). Technicals are mixed and not signaling strong momentum, valuation is constrained by losses and no dividend support, and corporate events add meaningful regulatory risk due to the FDA partial clinical hold despite some positive pipeline updates and stated cash runway.

Positive Factors

Proprietary delivery platform

A demonstrable delivery advantage addresses a structural barrier for muscle-targeted oligonucleotides. Superior cellular and nuclear uptake can materially raise the probability of clinical and commercial success across multiple neuromuscular indications, creating a durable technical differentiation and licensing appeal.

Regulatory progress and IP protection

Broader international regulatory clearances expand patient access and de-risk global development execution while a composition-of-matter patent through 2042 secures exclusivity. Together these structural elements enhance long-term commercial optionality and make partnerships or premium pricing more achievable if clinical benefit is shown.

Relatively conservative leverage and runway

Modest leverage and a strengthened equity base reduce short-term refinancing pressure, enabling continued clinical execution. A multi-year runway (into H2 2027) provides operational visibility to reach key 2026 readouts and value-inflecting milestones before near-term external financing becomes necessary.

Negative Factors

No revenue and persistent losses

The absence of revenue with sustained, large net losses reflects a research-stage business model that requires ongoing capital. Over the medium term, continued operating deficits will erode equity, necessitate external financing, and increase dilution risk unless clinical success leads to partnerships or product commercialization.

FDA partial clinical hold

A regulator-imposed partial hold can materially delay U.S. enrollment, force additional studies, and change program timelines and costs. For a single-lead program company, prolonged regulatory questions increase execution risk, may impair investor and partner confidence, and could reduce the commercial window if competitors advance.

Negative returns and capital erosion

Deeply negative returns on equity indicate that capital is being consumed faster than value is created. Persistent negative ROE signals structural inefficiency in converting R&D spend into value, heightening the likelihood of dilution, strategic exits, or program prioritization that may delay broader pipeline development.

PepGen Inc. Business Overview & Revenue Model

Company Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

PepGen Inc. generates revenue primarily through the development and commercialization of its proprietary therapies and drug candidates. The company's revenue model includes licensing agreements, collaborations, and strategic partnerships with pharmaceutical companies, which provide upfront payments, milestone payments, and royalties based on the successful development and commercialization of its therapies. Additionally, PepGen may engage in research and development collaborations that offer financial support in exchange for access to its innovative EDO platform. Key factors contributing to its earnings include the successful advancement of its clinical pipeline and the establishment of strong partnerships within the biotech and pharmaceutical industries.

PepGen Inc. Financial Statement Overview

Summary

Development-stage profile with no reported revenue (2020–2025), persistent large net losses (about -$89.7M in 2025), and heavy ongoing cash burn (FCF about -$82.0M in 2025). Balance sheet leverage is modest and equity increased in 2025, but deeply negative ROE and sustained burn keep financial risk elevated.

Income Statement

PEPG shows no reported revenue across 2020–2025, while losses remain very large and persistent. Net loss widened materially from 2020 (-$1.9M) to 2024 (-$90.0M) and stayed elevated in 2025 (-$89.7M), indicating a cost base that has scaled up without commercialization. Profitability remains structurally weak, with negative operating results in every period and no margin support from revenue.

Balance Sheet

The balance sheet is a relative bright spot: leverage is modest, with debt-to-equity improving to ~0.12 in 2025 (down from ~0.19 in 2023). Equity increased to $147.4M in 2025 from $118.6M in 2024, supporting liquidity and funding capacity. The key weakness is continued value erosion from losses, reflected in deeply negative returns on equity (about -61% in 2025), which can pressure the capital base over time if losses persist.

Cash Flow

Cash generation is consistently negative, with operating cash flow at -$81.6M in 2025 and free cash flow at -$82.0M, reflecting heavy cash burn. Free cash flow deteriorated in 2025 (growth of -4.5 versus 2024), suggesting limited near-term improvement in funding needs. A modest positive is that free cash flow broadly tracks net loss (roughly one-to-one), implying losses are not being substantially worsened by additional working-capital or non-cash distortions—but the magnitude of burn remains the dominant concern.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.40M	-1.50M	-1.18M	0.00	0.00
EBITDA	-92.22M	-89.09M	-83.58M	-67.81M	-26.93M
Net Income	-89.66M	-89.98M	-78.63M	-69.10M	-27.28M
Balance Sheet
Total Assets	173.91M	150.88M	143.05M	217.44M	143.64M
Cash, Cash Equivalents and Short-Term Investments	148.46M	120.19M	110.41M	181.75M	132.90M
Total Debt	17.00M	18.66M	20.10M	24.53M	0.00
Total Liabilities	26.46M	32.26M	34.63M	37.81M	10.55M
Stockholders Equity	147.44M	118.62M	108.42M	179.63M	133.09M
Cash Flow
Free Cash Flow	-81.90M	-82.87M	-71.60M	-63.02M	-23.10M
Operating Cash Flow	-81.64M	-82.37M	-69.00M	-59.27M	-22.60M
Investing Cash Flow	-15.23M	-37.67M	-32.00M	-3.75M	-500.00K
Financing Cash Flow	107.98M	88.75M	-189.00K	112.19M	147.66M

PepGen Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.57
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PEPG, the sentiment is Negative. The current price of 5.57 is below the 20-day moving average (MA) of 6.17, below the 50-day MA of 5.89, and above the 200-day MA of 3.69, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 44.95 is Neutral, neither overbought nor oversold. The STOCH value of 27.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PEPG.

PepGen Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYEL	52 Neutral	$544.48M	-1.91	-96.68%	―	-34.92%	-43.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCKT	49 Neutral	$575.42M	-1.75	-65.76%	―	―	18.39%
PEPG	47 Neutral	$425.75M	-3.07	-75.73%	―	―	4.71%
EDIT	46 Neutral	$258.38M	-1.14	-348.55%	―	-24.90%	7.19%
LXEO	46 Neutral	$525.51M	-4.99	-90.49%	―	―	4.97%

PepGen Inc. Corporate Events

PepGen Updates EDO Platform and DM1 Program Outlook

On March 4, 2026, PepGen Inc. released an updated corporate presentation detailing progress on its EDO platform and lead candidate PGN-EDODM1 for myotonic dystrophy type 1, highlighting best-in-class potential based on high levels of splicing correction, a favorable emerging safety profile and selective targeting of pathogenic DMPK RNA. The company reported global regulatory clearances enabling enrollment in its FREEDOM2-DM1 trial, outlined clinical data milestones expected in 2026 and indicated a cash runway into the second half of 2027, underscoring operational visibility as it advances a differentiated neuromuscular pipeline in a large, unmet market with no approved disease-modifying therapies.

PepGen emphasized that its EDO technology substantially improves cellular and nuclear uptake of oligonucleotides compared with naked oligos, addressing a long-standing delivery challenge in muscle tissue. The updated materials also reinforced the company’s strategy to leverage this platform in additional genetic neuromuscular indications, such as Charcot-Marie-Tooth disease, potentially strengthening its competitive positioning in next-generation RNA-targeted therapies.

The most recent analyst rating on (PEPG) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.

PepGen Faces FDA Partial Hold Amid Ongoing FREEDOM2 Trial

On March 4, 2026, PepGen reported fourth-quarter and full-year 2025 results and disclosed that the U.S. Food and Drug Administration had placed a partial clinical hold on the U.S. arm of its Phase 2 FREEDOM2-DM1 trial of PGN-EDODM1, citing questions about preclinical pharmacology and toxicology data rather than clinical findings. The company continues dosing 10 mg/kg cohorts in Canada and the U.K., has expanded trial sites to South Korea, Australia and New Zealand, and is moving forward with open-label extension studies while working with regulators, as Phase 1 data presented at major 2025 and upcoming 2026 conferences showed robust splicing correction, generally favorable safety, and support for its best-in-class aspirations.

Financially, PepGen ended 2025 with $148.5 million in cash, cash equivalents and marketable securities, guiding that this runway should fund operations into the second half of 2027 despite an annual net loss of $89.7 million and modestly lower research and development spending year over year. Recent corporate developments include the appointment of a new Chief Business and Legal Officer and issuance of a key U.S. composition-of-matter patent expected to protect PGN-EDODM1 into 2042, developments that strengthen the company’s legal and intellectual property position as it advances its neuromuscular pipeline under the shadow of the FDA’s partial hold.

The most recent analyst rating on (PEPG) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.

PepGen Inc. Appoints New Chief Business Officer

On December 8, 2025, PepGen Inc. announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Vittiglio, who has extensive experience in legal and business leadership within the biotechnology sector, is expected to play a key role in guiding PepGen through complex transactions and strategic partnerships as the company progresses with its PGN-EDODM1 program and prepares for the 2026 readouts from its FREEDOM2-EDODM1 study.

The most recent analyst rating on (PEPG) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.